Canakinumab, a human IgG1 anti-IL-1β monoclonal antibody initially approved for rheumatoid arthritis, has been successfully repurposed for MWS, an autoinflammatory rare disorder caused by increased IL-1 [9]. The gene discussed is IL1B; the disease is Muckle-Wells syndrome.